Drug profile · INN
pitavastatin calcium
PITAVASTATIN CALCIUM
pitavastatin calcium (PITAVASTATIN CALCIUM) is a hmg-coa reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — pitavastatin calcium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
pitavastatin calcium (PITAVASTATIN CALCIUM) is a hmg-coa reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
HMG-CoA reductase inhibitor
Primary target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pitavastatin calcium?
pitavastatin calcium (PITAVASTATIN CALCIUM) is a hmg-coa reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pitavastatin calcium?
PITAVASTATIN CALCIUM is a marketed brand name for pitavastatin calcium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pitavastatin calcium?
pitavastatin calcium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.